Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants

BACKGROUND: The variability in cost of palivizumab treatment, indicated for prevention of respiratory syncytial virus (RSV) infections in high-risk infants, has not been robustly estimated in prior studies. This study aimed to determine the cost variations of palivizumab from a US payer perspective...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahabi, Ahva, Peneva, Desi, Incerti, Devin, McLaurin, Kimmie, Stevens, Warren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820240/
https://www.ncbi.nlm.nih.gov/pubmed/29464672
http://dx.doi.org/10.1007/s41669-017-0042-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820240/
https://www.ncbi.nlm.nih.gov/pubmed/29464672
http://dx.doi.org/10.1007/s41669-017-0042-3

Ejemplares similares